page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Flurbiprofen (Ansaid, Ocufen)

Category:

  • Analgesic

Description:

  • NSAID, non-narcotic analgesic

Indications:

  • Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis

  • Inhibition of inoperative miosis (ophth), cystoid macular edema (non-FDA approved)

  • Inflammation after cataract or glaucoma laser surgery or uveitis syndromes (ophth: non-FDA approved)

  • Bursitis, primary dysmenorrhea, tendinitis, acute gout (all non-FDA approved)

Contraindications:

  • Dendritic keratitis (ophth)

Precautions:

  • Pregnancy category C; excreted in breast milk; use caution in nursing mothers

  • Bleeding tendencies, peptic ulcer

  • Hepatic/renal function impairment, elderly, CHF, hypertension

Adverse Reactions (Side Effects):

  • CNS: dizziness, headache, lightheadedness

  • CV: chest pain, CHF, dysrhythmias, edema, hyper/hypotension, palpitation, tachycardia

  • EENT: burning or stinging upon instillation, dry eyes, hearing disturbances, photophobia, tinnitus, visual disturbances

  • GI: abdominal cramps, constipation, diarrhea, dyspepsia, flatulence, gastric or duodenal ulcer with bleeding or perforation, hepatitis, nausea, occult blood in stool, pancreatitis, vomiting

  • GU: renal failure

  • HEME: agranulocytosis, eosinophilia, leukopenia, pancytopenia, thrombocytopenia

  • METAB: hyperglycemia, hyperkalemia, hypoglycemia, hyponatremia,

  • RESP: bronchospasm, dyspnea

  • SKIN: photosensitivity, rash, urticaria

Dosage:

  • Administered orally and ophthalmic instillation

  • Adult:            

    • Rheumatoid and osteoarthritis: PO 200-300mg daily divided 2-4 times daily

    • Dysmenorrhea: PO 50mg daily

    • Inhibition of intraoperative miosis: OPHTH 1 drop every 30 minutes beginning 2 hours before surgery (total 4 drops)

Drug interactions:

  • Warfarin: addition of flurbiprofen associated with excessive hypoprothrombinemia and bleeding; ibuprofen less likely to interact

  • Methotrexate: addition of flurbiprofen may interfere with the renal secretion of methotrexate, yielding increased risk of methotrexate toxicity

  • Prednisone: increase risk of GI ulceration

  • Loop diuretics: reduction in diuretic and antihypertensive effects

 

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site